Anavex Life Sciences Corp.

Contributing Author

Recent Articles by Anavex Life Sciences Corp.

Jan-13	Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer's Disease AVXL GlobeNewswire
Jan-08	Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology AVXL GlobeNewswire
Jan-06	Anavex Life Sciences Receives FDA Feedback on Alzheimer's Disease Program AVXL GlobeNewswire
Dec-18	Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion AVXL GlobeNewswire
Dec-12	Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer's Disease AVXL GlobeNewswire
Nov-26	Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference AVXL GlobeNewswire
Nov-25	Anavex Life Sciences Reports Fiscal 2025 Fourth Quarter Financial Results and Provides Business Update AVXL GlobeNewswire
Nov-19	Anavex Life Sciences to Present at the 44TH ANNUAL J.P. MORGAN Healthcare Conference AVXL GlobeNewswire
Nov-18	Anavex Life Sciences to Announce Fiscal 2025 Fourth Quarter Financial Results on Tuesday, November 25, 2025 AVXL GlobeNewswire
Nov-14	Anavex Life Sciences Provides Regulatory Update on Blarcamesine for Early Alzheimer's Disease AVXL GlobeNewswire
Oct-29	Anavex Life Sciences Announces Continued Long-Term Benefit from Oral Blarcamesine Compared to Decline Observed in the Alzheimer's Disease Neuroimaging Initiative (ADNI) Control Group AVXL GlobeNewswire
Oct-10	Anavex Life Sciences Announces Presentation at the 35th Alzheimer Europe Conference 'Connecting Science and Communities: The Future of Dementia Care' AVXL GlobeNewswire
Oct-02	Anavex Life Sciences Announces Successful Development of Once-Daily Oral Tablet Formulation for the ANAVEX3-71 Program AVXL GlobeNewswire
Oct-02	Anavex Life Sciences Announces Positive Topline Results from Phase 2 Study of ANAVEX3-71 for the Treatment of Schizophrenia AVXL GlobeNewswire
Sep-30	Anavex Life Sciences Announces Publication of Oral Blarcamesine Describing a New Class of Clinical Precision Medicine from Phase IIb/III Alzheimer's Disease Trial AVXL GlobeNewswire
Sep-09	Anavex Life Sciences Announces Oral Blarcamesine Cognitive Resilience Results Approximating Normal Aging in New Precision Medicine Clinical Data from Phase IIb/III Alzheimer's Disease Trial AVXL GlobeNewswire
Sep-02	Anavex Life Sciences to Present at the H.C. Wainwright 27th Annual Global Investment Conference 2025 AVXL GlobeNewswire
Aug-26	Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Established Precise Autophagy Mechanism with Blarcamesine AVXL GlobeNewswire
Aug-20	Anavex Life Sciences Announces New Publication in Medical Journal: Blarcamesine Prevented Cognitive Impairment in Animal Model of Alzheimer's Disease AVXL GlobeNewswire
Aug-12	Anavex Life Sciences Reports Fiscal 2025 Third Quarter Financial Results and Provides Business Update AVXL GlobeNewswire
Aug-05	Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 AVXL GlobeNewswire
Jul-31	Anavex Life Sciences Announces Positive Precision Medicine Results from up to 4-Years of Oral Blarcamesine Treatment in Phase IIb/III Open-Label Extension Trial in Early Alzheimer's Disease AVXL GlobeNewswire
May-14	Anavex Life Sciences to Participate at Upcoming Healthcare Conferences AVXL GlobeNewswire
May-13	Anavex Life Sciences Reports Fiscal 2025 Second Quarter Financial Results and Provides Business Update AVXL GlobeNewswire
May-06	Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025 AVXL GlobeNewswire

Anavex Life Sciences Corp.

Recent Articles by Anavex Life Sciences Corp.

Upgrade your FINVIZ experience